XML 84 R73.htm IDEA: XBRL DOCUMENT v3.24.3
Sale of Pegzilarginase to Immedica (Details) - USD ($)
12 Months Ended
Jul. 27, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Proceeds from sale of intangible assets   $ 15,000,000 $ 0 $ 0
Gain on sale of in-process research and development asset   $ 16,449,000 $ 0 $ 0
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Global Rights To Pegzilarginase        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Proceeds from sale of intangible assets $ 15,000,000.0      
Contingent consideration 100,000,000.0      
Carrying value of assets 0      
Gain on sale of in-process research and development asset 16,400,000      
Contingent reimbursement of pre-paid manufacturing costs 1,800,000      
Derecognition of nonfinancial assets and liabilities $ 400,000